Patents by Inventor Jonathan C. Kagan

Jonathan C. Kagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists
    Publication number: 20250025552
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Application
    Filed: July 17, 2024
    Publication date: January 23, 2025
    Inventor: Jonathan C. Kagan
  • PRO-INFLAMMATORY AND ANTI-CANCER FUNCTIONS OF TOLL-LIKE RECEPTOR 4 ANTAGONISTS
    Publication number: 20240415957
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Application
    Filed: June 18, 2024
    Publication date: December 19, 2024
    Inventor: Jonathan C. Kagan
  • Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
    Patent number: 12070499
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Grant
    Filed: April 26, 2022
    Date of Patent: August 27, 2024
    Assignee: Children's Medical Center Corporation
    Inventor: Jonathan C. Kagan
  • Pro-inflammatory and anti-cancer functions of toll-like receptor 4 antagonists
    Patent number: 12053522
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: August 6, 2024
    Assignee: Children's Medical Center Corporation
    Inventor: Jonathan C. Kagan
  • Nucleic Acids That Manipulate Immune Pathways
    Publication number: 20240158453
    Abstract: The present invention provides methods and compositions of synthetic novel genes to manipulate signaling pathways of the immune system.
    Type: Application
    Filed: June 26, 2023
    Publication date: May 16, 2024
    Inventors: Jonathan C. Kagan, Yunhao Tan
  • Immunomodulatory lipopolysaccharide compositions
    Patent number: 11878057
    Abstract: Provided herein are lipid A molecules engineered from Moritella lipopolysaccharides and uses thereof.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: January 23, 2024
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE CHILDREN'S MEDCIAL CENTER CORPORATION, MINISTRY OF FISHERIES AND MARINE RESOURCES DEVELOPMENT
    Inventors: Randi Dawn Rotjan, Anna Gauthier, Aranteiti Tekiau, Jonathan C. Kagan
  • STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY
    Publication number: 20230076515
    Abstract: The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy. Accordingly, described herein are methods of inducing or enhancing an adaptive immune response to a cancer in a subject and methods of treating cancer in a subject. In some embodiments, the methods hyperactivate dendritic cells (DCs), which induce T helper type I (TH1) and cytotoxic T lymphocyte (CTL) responses in the absence of TH2 immunity.
    Type: Application
    Filed: November 18, 2020
    Publication date: March 9, 2023
    Inventors: Jonathan C. Kagan, Dania Zhivaki
  • PRO-INFLAMMATORY AND ANTI-CANCER FUNCTIONS OF TOLL-LIKE RECEPTOR 4 ANTAGONISTS
    Publication number: 20230053338
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Application
    Filed: May 9, 2022
    Publication date: February 23, 2023
    Inventor: Jonathan C. Kagan
  • Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists
    Publication number: 20230042429
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Application
    Filed: April 26, 2022
    Publication date: February 9, 2023
    Inventor: Jonathan C. Kagan
  • Hyperactive Dendritic Cells Enable Durable Adoptive Cell Transfer-Based Anti-Tumor Immunity
    Publication number: 20220401535
    Abstract: The present application is related to cancer immunotherapy, e.g. stimulation of T cell mediated anti-tumor therapy.
    Type: Application
    Filed: November 18, 2020
    Publication date: December 22, 2022
    Inventors: Jonathan C. Kagan, Dania Zhivaki
  • Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
    Patent number: 11400153
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: August 2, 2022
    Assignee: Children's Medical Center Corporation
    Inventor: Jonathan C. Kagan
  • IMMUNOMODULATORY LIPOPOLYSACCHARIDE COMPOSITIONS
    Publication number: 20220184206
    Abstract: Provided herein are lipid A molecules engineered from Moritella lipopolysaccharides and uses thereof.
    Type: Application
    Filed: December 10, 2021
    Publication date: June 16, 2022
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: RANDI DAWN ROTJAN, ANNA GAUTHIER, ARANTEITI TEKIAU, JONATHAN C. KAGAN
  • TARGETED SYNERGISTIC CANCER IMMUNOTHERAPY
    Publication number: 20220175926
    Abstract: Reactive oxygen species (ROS) generated with noninvasive ultrasound and sonosensitizers, potently synergize with selected immunomodulators to hyperactivate dendritic cells and macrophages at desired locations and times within the body. Together with the tumor antigens provided by dying/dead tumor cells, these signals can result in activation of adaptive immune responses. This approach is useful for eliciting T cell responses within tumors present in any tissue of the body.
    Type: Application
    Filed: March 30, 2020
    Publication date: June 9, 2022
    Inventors: Jeffrey M. KARP, Rui KUAI, Jun XU, Wenmin YUAN, Dania ZHIVAKI, Jonathan C. KAGAN, Andrew BELLINGER
  • Pro-inflammatory and anti-cancer functions of toll-like receptor 4 antagonists
    Patent number: 11351250
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: June 7, 2022
    Assignee: Children's Medical Center Corporation
    Inventor: Jonathan C. Kagan
  • Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists
    Publication number: 20200405847
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Inventor: Jonathan C. Kagan
  • PRO-INFLAMMATORY AND ANTI-CANCER FUNCTIONS OF TOLL-LIKE RECEPTOR 4 ANTAGONISTS
    Publication number: 20200405848
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Inventor: Jonathan C. Kagan
  • NUCLEIC ACIDS THAT MANIPULATE IMMUNE PATHWAYS
    Publication number: 20200216506
    Abstract: The present invention provides methods and compositions of synthetic novel genes to manipulate signaling pathways of the immune system.
    Type: Application
    Filed: May 12, 2018
    Publication date: July 9, 2020
    Inventors: Jonathan C. Kagan, Yunhao Tan
  • Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists
    Publication number: 20180318414
    Abstract: The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were identified to promote DC-mediated immunity, and are provided as adjuvants in immunostimulatory compositions, including vaccines.
    Type: Application
    Filed: January 12, 2016
    Publication date: November 8, 2018
    Inventor: Jonathan C. Kagan
  • Modulators of antiviral signaling pathways and therapeutic uses thereof
    Patent number: 9650427
    Abstract: The invention provides methods, compositions, and kits featuring novel RIG-I like receptor activators or inhibitors for use in preventing or treating virus infection or autoimmune disease.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: May 16, 2017
    Assignee: Children's Medical Center Corporation
    Inventor: Jonathan C. Kagan
  • MODULATORS OF ANTIVIRAL SIGNALING PATHWAYS AND THERAPEUTIC USES THEREOF
    Publication number: 20150037362
    Abstract: The invention provides methods, compositions, and kits featuring novel RIG-I like receptor activators or inhibitors for use in preventing or treating virus infection or autoimmune disease.
    Type: Application
    Filed: July 23, 2012
    Publication date: February 5, 2015
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventor: Jonathan C. Kagan